Trial design-OV15

AGO-OVAR 17/BOOST

Clinical Trial Study: OV15

A prospective randomized Phase III trial to evaluate optimal
treatment duration of first-line bevacizumab in combination
with carboplatin and paclitaxel in patients with primary
epithelial ovarian, fallopian tube or peritoneal cancer.

Study design